Document Detail


Stroke and atherothrombosis: an update on the role of antiplatelet therapy.
MedLine Citation:
PMID:  18705896     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Atherothrombosis is responsible for most acute ischemic manifestations of atherosclerotic disease, including stroke. Individuals with evidence of atherothrombotic disease in one vascular bed have a significant risk of recurrence and show increased vulnerability over time for other manifestations elsewhere in the vasculature. Ischemic event rates for asymptomatic patients with multiple atherothrombotic risk factors appear to be similar to those in patients with documented cardiovascular disease. For example, diabetes mellitus and obesity are found at alarmingly high rates in patients with prior cardiovascular events, including stroke or transient ischemic attacks. Antiplatelet therapy is a key component of atherothrombotic event prevention. The results of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) study showed that while dual antiplatelet therapy with aspirin and clopidogrel may not play a role in primary prevention, post hoc analysis alluded to the possibility of benefit for dual antiplatelet therapy in certain populations of stroke patients. We examined current recommendations for the prevention of atherothrombotic events, focusing on the role of oral antiplatelet agents in patients with ischemic stroke.
Authors:
Andrei V Alexandrov; Peter Alagona
Related Documents :
9077506 - Hyperkinetic movement disorders during and after acute stroke: the lausanne stroke regi...
20537496 - An unfavorable dietary pattern is associated with symptomatic ischemic stroke and carot...
8422846 - Risk factors for developing seizures after a stroke.
20444626 - Neurovascular complications of cocaine use at a tertiary stroke center.
15925866 - Role of interleukin-1beta in the development of malnutrition in chronic renal failure p...
22165676 - Credibility of the measurement of serum ferritin and transferrin receptor as indicators...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  International journal of stroke : official journal of the International Stroke Society     Volume:  3     ISSN:  1747-4949     ISO Abbreviation:  -     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-08-18     Completed Date:  2008-11-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101274068     Medline TA:  Int J Stroke     Country:  England    
Other Details:
Languages:  eng     Pagination:  175-81     Citation Subset:  IM    
Affiliation:
Comprehensive Stroke Center, University of Alabama, Birmingham, AL 35294-0017, USA. avalexandrov@att.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Atherosclerosis / drug therapy,  prevention & control*
Delayed-Action Preparations
Dipyridamole / administration & dosage,  therapeutic use*
Embolism, Cholesterol / drug therapy,  prevention & control*
Humans
Platelet Aggregation Inhibitors / therapeutic use*
Risk Assessment
Risk Factors
Stroke / drug therapy,  prevention & control*
Chemical
Reg. No./Substance:
0/Delayed-Action Preparations; 0/Platelet Aggregation Inhibitors; 58-32-2/Dipyridamole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ischemic perinatal stroke: challenge and opportunities.
Next Document:  Setting up an acute stroke service.